



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C12N 15/11, 15/86, C07K 14/315, C12N 5/10, A61K 39/09, 39/39, 39/395, 47/48, C07K 19/00, G01N 33/577, A01K 67/027</p>	A1	<p>(11) International Publication Number: WO 99/54457</p> <p>(43) International Publication Date: 28 October 1999 (28.10.99)</p>
<p>(21) International Application Number: PCT/IB99/00799</p> <p>(22) International Filing Date: 20 April 1999 (20.04.99)</p> <p>(30) Priority Data: 9808327.2 20 April 1998 (20.04.98) GB</p> <p>(71) Applicant (for all designated States except US): CHIRON S.P.A. [IT/IT]; Via Fiorentina, 1, I-53100 Siena (IT).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): TETI, Giuseppe [IT/IT]; Piazza Juvara, 3, IS464, I-98121 Messina (IT). POLONELLI, Luciano [IT/IT]; Viale Campanini, 17, I-43100 Parma (IT).</p> <p>(74) Agent: HALLYBONE, Huw, George; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).</p>	<p>(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p>	
<p>(54) Title: VACCINE FORMULATIONS COMPRISING ANTIIDIOTYPIC ANTIBODIES WHICH IMMUNOLOGICALLY MIMIC GROUP B STREPTOCOCCAL CARBOHYDRATES</p>		
<p>(57) Abstract</p> <p>The invention relates to peptide, oligopeptide or polypeptide compounds that are capable of eliciting a protective immune response against the capsular polysaccharide of group B <i>Streptococcus</i> (GBS), particularly type III GBS. Such compounds are useful in the development of vaccines that are effective against diseases caused by these pathogens.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakistan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

VACCINE FORMULATIONS COMPRISING ANTIDIOTYPIC ANTIBODIES WHICH IMMUNOLOGICALLY MIMIC GROUP B STREPTOCOCCAL CARBOHYDRATES

The present invention relates to compounds that are capable of eliciting a protective immune response against the capsular polysaccharide of group B *Streptococcus* (GBS), particularly type III GBS. Such compounds are useful in the development of vaccines that are effective against diseases caused by these pathogens.

Group B streptococci (GBS) are recognised as a major cause of sepsis and meningitis in neonates and in susceptible adult patients such as those suffering from diabetes, cirrhosis and solid tumours. Although the use of antibiotics has had a dramatic impact on case fatality rate, the attack rates for infection have changed little. Indeed, even in industrialised countries, the incidence of mortality and permanent disability remains high in spite of appropriate therapy being applied.

GBS are classified into serotypes based on specific type of capsular polysaccharides (CHO) possessed by the organism. The capsular polysaccharide has anti-phagocytic properties and is considered to be the main virulence factor of GBS (Baker *et al.*, 1995; Rubens *et al.*, 1987). Capsular type III GBS are responsible for the majority of neonatal infection and for approximately 90% of meningitis cases (Baker *et al.*, 1995).

Immunisation of fertile women with a combination of type-antigens has been proposed as a strategy for the prevention of neonatal disease, with the rationale that specific antibodies passing through the placental barrier can prevent neonatal infection (Baker *et al.*, 1981). Indeed, a significant correlation has been shown between GBS infection in neonates and low levels of maternal antibodies to the type-specific CHO (Baker *et al.*, 1981; Baker *et al.*, 1976).

Polysaccharide vaccines have been developed in an attempt to control the incidence of diseases caused by GBS. The major problem with the capsular polysaccharide vaccines is their poor immunogenicity. This is believed to derive from the T-cell independent (TI) type of immune reaction that is the only antibody response used by the body against polysaccharide antigens. This type of response does not involve MHC Class II

restriction molecules for antigen presentation to T-cells; as a consequence, T-cell help is prevented.

5 A widely accepted method to potentiate the immunogenicity of polysaccharide antigens is by their conjugation with proteins. To a large extent, this approach has been successful in the prevention of *Haemophilus influenzae* type b infections (Ala'Aldeen and Hormaeche, 1995). Type CHOs conjugated with tetanus toxoid (Paoletti *et al.*, 1994; Kasper *et al.*, 1996; Baker *et al.*, 1996) or GBS proteins (Madoff *et al.*, 1992; Larsson *et al.*, 1996) are currently being evaluated as potential vaccines for the
10 prevention of GBS disease.

An alternative strategy to obtain effective and boostable antibody responses against carbohydrate antigens involves the development of protein molecules mimicking the conformation of relevant carbohydrate epitopes. The advantage of this approach is
15 that, by their chemical nature, proteins have an intrinsic ability to stimulate T cell help in an antigen-specific way. This strategy resulted in the development of a monoclonal antiidiotypic antibody (mAb) coupled to a carrier protein that was successfully used as a surrogate vaccine to immunoprotect BALB/c mice against lethal *Streptococcus pneumoniae* infection (McNamara *et al.*, 1984). Monoclonal antibodies mimicking the
20 K13 *Escherichia coli* (Stein *et al.*, 1984) and the group C *Neisseria meningitidis* (Westerink *et al.*, 1988) capsular antigens have also been described.

However, although these reports illustrate the concept that compounds can be generated that to some extent mimic the antigenic determinants of capsular polysaccharides, it is
25 widely-appreciated in the art that the specific compounds developed so far (mouse monoclonal antibodies) are unlikely human vaccine candidates and are often ineffective in conferring long-lasting protective immunity. Furthermore, no such compounds have to date been generated that are effective against GBS.

30 There thus remains a great need for the development of new, improved vaccine strategies that are effective in combating diseases caused by GBS and in particular for a compound that is capable of eliciting a protective immune response against GBS when used as a vaccine.

SUMMARY OF THE INVENTION

5 According to the present invention there is provided a peptide, oligopeptide or polypeptide compound that is capable of eliciting a protective immune response against the capsular polysaccharide of group B *Streptococcus*. Such compounds are useful as immunogenic compounds and may in turn be useful as components of vaccines that are protective against diseases caused by GBS.

10 Preferably, the compounds are capable of eliciting a protective immune response against the type III capsular polysaccharide of group B *Streptococcus*, which is widely recognised as being the major virulence determinant of GBS. Neonatal protection can be obtained by immunising mothers with these compounds.

15 By the term "protective immune response" is meant the development of a beneficial humoral response and/or a cellular response that is directed against the compound of the invention in an animal or human patient. A humoral response is antibody-mediated and involves the generation of antibodies with affinity for the compounds of the invention. This means that upon GBS invasion of an individual who has been immunised with a
20 compound according to the invention, the individual's immune system will possess an immunologic memory of the compound and will be therefore able to mount an immediate humoral attack against the GBS organisms.

A cellular response is elicited by the presentation of antigenic epitopes in association
25 with Class I or Class II molecules of the major histocompatibility complex (MHC). This activates antigen-specific CD4+ T helper cells or CD8+ cytotoxic T lymphocyte cells.

Species in which the compounds of the present invention may be effective in eliciting an immune response include all mammals, especially humans. In most cases, it will be
30 preferred that the compounds are active eliciting an immune response in humans. The population of humans that are in greatest need of protection from disease caused by GBS are neonates. However, various sectors of the adult population are also at risk,

particularly those who are suffering from debilitating chronic disease such as diabetes, cirrhosis or who carry a solid tumour.

5 An effective strategy to protect neonates involves the elicitation, in mothers, of antibodies that are capable of crossing the placental barrier. Such antibodies belong to the IgG class and are produced only in response to antigens capable of stimulating both B and T lymphocytes (T-dependent antigens). The compounds provided according to the present invention have the ability to stimulate the production of specific IgG. Moreover, maternal immunisation with these compounds is effective to protect neonates
10 from GBS disease.

By peptide is meant a compound of between 3 and 10 amino acids covalently coupled together. An oligopeptide will comprise between 10 and 30 linked amino acids, whilst a polypeptide will contain greater than 30 amino acids.

15

The structure of the peptide, oligopeptide or polypeptide compounds according to the invention will be such as to contain in the folded three-dimensional structure an epitope that mimics an immunological determinant group of the capsular polysaccharide of group B *Streptococcus*. Preferably, this epitope mimics an immunological determinant
20 group of the type III capsular polysaccharide of group B *Streptococcus*.

Peptides and oligopeptides are ideal candidates for use as immunogenic compounds due to their small size; these molecules are sufficiently large to mimic antigenic epitopes (that are typically determined by between 5 and 12 amino acids), yet are small enough
25 to possess pharmacokinetic properties that are advantageous over those of more bulky molecules such as immunoglobulins. By their chemical nature, these molecules possess an intrinsic ability to stimulate T cell help in an antigen-specific fashion, a property not possessed, for example by polysaccharides. This is one reason why the use of polysaccharide vaccines suffers inherent drawbacks in the treatment of diseases caused
30 by capsular pathogens.

Polypeptide compounds according to the invention may also possess advantageous properties that suit these compounds to certain applications. The properties of these

molecules can be precisely tailored as desired, for example by grafting an Fc domain onto the molecule in order to allow recruitment of various effectors of the immune system.

5 According to a preferred embodiment of the present invention, a polypeptide compound effective in eliciting the desired immune response against the capsular polysaccharide of GBS may comprise an scFv fragment. These molecules are small and therefore possess advantageous pharmacokinetic properties. Their small size also means that production of anti-scFv antibodies will be minimised. The generation of an anti-scFv response may
10 also be minimised by constructing the scFv from molecules derived from the same species as the subject animal to be immunised. Most preferably, the compound of the present invention comprises the scFv C10, generated by selection of an scFv phage display library using the anti-type III CHO P9D8 mAb (Teti *et al.*, 1992).

15 The peptides, oligopeptides or polypeptide compounds of the present invention may be fused to carrier proteins. A carrier protein is an antigenic polypeptide entity that induces the formation of antibodies directed against an antigen that is conjugated to it, by the immune system of an organism into which the carrier-antigen conjugate is introduced. The necessity to use carrier proteins derives from the fact that although many short
20 epitopes are protective, they are often poorly immunogenic. This negates the usefulness of these epitopes in the generation of new and efficacious vaccines. By conjugating an immunogenic carrier protein to a molecule that is non-immunogenic, it is possible to confer the high immunogenicity of the carrier protein onto the conjugate molecule. Such conjugate molecules stimulate the generation of an immune response against the non-
25 immunogenic portion of the conjugate molecule and thus have been used effectively in vaccines that protect against pathogens for which protective immunity could not otherwise be generated.

Suitable carrier proteins comprise conventionally-used carriers such as the highly
30 immunogenic tetanus toxoid protein, *Plasmodium falciparum* circumsporozoite, hepatitis B surface antigen, hepatitis B nuclear core protein, *H. influenzae* matrix protein, *H. influenzae* haemagglutinin diphtheria toxoid, non-toxic diphtheria toxin mutant CRM 197, group B *N. meningitidis* outer membrane protein complex (OMPC), the pneumococcal

toxin pneumolysin, and heat shock proteins from *Mycobacterium bovis*. Other suitable carrier proteins will be known to those of skill in the art. Improved carrier proteins have recently been developed containing CD4⁺ T_h cell epitopes that do not contain T cell suppressor functions; these carriers will also be suitable for use in conjunction with the
5 compounds of the present invention.

In addition to carrier proteins, the compounds of the present invention may comprise other peptides or protein fragments, such as epitopes from immunomodulating cytokines such as interleukin-2 (IL-2) or granulocyte-macrophage colony stimulating
10 factor (GM-CSF). Promiscuous peptides (Panina-Bordignon *et al.* 1989), the so-called "universal" peptides (Kumar *et al.*, 1992), cluster peptides (Ahlers *et al.*, 1993) or peptides containing both T cell and B cell epitopes (Lett *et al.*, 1994) may also be used to recruit various effector systems of the immune system, as required.

15 The peptide, oligopeptide or polypeptide compounds of the present invention may be generated by any suitable means, as will be apparent to those of skill in the art. In the case of peptides, combinatorial peptide libraries will be most suitable; peptide molecules displaying the desired binding characteristics can be isolated through selection regimes that select for molecules that bind to antibodies that are specific for
20 GBS capsular polysaccharide, preferably type III capsular polysaccharide (for example the anti-type III CHO mAb P9D8).

One method of generation of peptide libraries utilises degenerate oligonucleotide libraries. This method allows the subsequent analysis of the encoding nucleic acid and
25 thus gives direct sequence information for the mimotope (see for example, Cull *et al.* 1992; Mattekakis *et al.*, 1994).

Phage display technology also provides a vehicle that allows for the selection of displayed peptides, oligopeptides or polypeptides and simultaneously provides a link
30 between phenotype and genotype so that the encoding nucleic acid can be identified and analysed (for a review see Clackson and Wells (1994) *Trends Biotechnol* **12**: 173-184). Filamentous phage particles act as genetic display packages with proteins on the outside and the nucleic acids which encode them on the inside. The practical limit on library

size allowed by this technology is of the order of 10^7 to 10^{11} variants, so allowing the generation of a huge number of different compounds. This technology also allows iterative rounds of selection to be performed, so honing the affinity of the molecules isolated.

5

The preferred method of generation of peptide, oligopeptide or polypeptide compounds according to the present invention is through selection of candidate compounds in a phage display library.

10 Selection of a nucleic acid or gene from a phage display library will in most cases require the screening of a large number of variant nucleic acids or genes. Libraries of nucleic acids or genes for use with phage display technology may be generated in a variety of ways. For example, pools of naturally-occurring genes may be cloned from genomic DNA or cDNA (see Sambrook *et al.*, 1989). Phage-antibody libraries, made by
15 PCR amplification repertoires of antibody genes from immunised or non-immunised donors have proved very effective sources of functional antibody fragments (Winter *et al.*, (1994) *Annu Rev Immunol*, **12**, 433-55; Hoogenboom, (1997) *Trends Biotechnol.*, **15**, 62-70).

20 Preferably, the compounds of the present invention are produced in phage display libraries containing nucleic acid pools derived from the mRNA of splenic lymphocytes of animals that have been immunised with anti-GBS antibody. Preferably the antibody used for immunisation of the animal is directed against the type III CHO of GBS. Most preferably, the antibody used is the P9D8 antibody.

25

Libraries of genes can also be made by encoding all or part of genes or pools of genes or by using randomised or doped synthetic oligonucleotides. Libraries can also be made by randomly introducing mutations into a gene or into a pool of genes by a variety of techniques *in vivo*, including using so-called 'mutator strains' of bacteria such as *E. coli mutD5* (Liao *et al.*, 1986). The antibody hypermutation system of B-lymphocytes may
30 also be used (Yelamos *et al.*, 1995).

Random mutations can also be introduced both *in vivo* and *in vitro* by chemical mutagens, and ionizing or UV irradiation (see Friedberg *et al.*, 1995), or by incorporation of mutagenic base analogues (Zaccolo *et al.*, 1996). Mutations can also be introduced into genes *in vitro* during polymerisation, for example by using error-prone polymerases
5 (Leung *et al.*, 1989). Further diversification can be introduced by using homologous recombination either *in vivo* (see Kowalczykowski *et al.*, 1994) or *in vitro* (Stemmer, 1994).

Once the peptide, oligopeptide, or polypeptide compound of the invention has been
10 isolated, the compound may be produced in larger amounts by any suitable means, as will be apparent to those of skill in the art. Two preferred methods of construction are direct synthesis and by production of recombinant protein. In the case of short peptides whose sequence is known, the preferable method of production may be by direct synthesis. However, in most cases, the preferable method will be by recombinant
15 means, by expression from an encoding nucleic acid molecule. Recombinant expression has the advantage that the production of the compound is inexpensive, safe, facile and does not involve the use of toxic compounds that may require subsequent removal.

When expressed in recombinant form, the compounds of the present invention will be
20 generated by expression from an encoding nucleic acid in a host cell. A variety of different expression systems may be used, for example those used with mammalian cells, baculoviruses, bacteria, and yeast. Preferably, bacterial hosts are used for the production of recombinant protein, due to the ease with which bacteria may be manipulated and grown. The bacterial host of choice is *Escherichia coli*.

25

Mammalian expression systems are known in the art. A mammalian promoter is any DNA sequence capable of binding mammalian RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiating region, which is usually placed proximal to
30 the 5' end of the coding sequence, and a TATA box, usually located 25-30 base pairs (bp) upstream of the transcription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site. A mammalian promoter will also contain an upstream promoter element, usually located within 100 to 200 bp

upstream of the TATA box. An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation [Sambrook et al. (1989) "Expression of Cloned Genes in Mammalian Cells." In *Molecular Cloning: A Laboratory Manual, 2nd ed.*].

5

Mammalian viral genes are often highly expressed and have a broad host range; therefore sequences encoding mammalian viral genes provide particularly useful promoter sequences. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter (Ad MLP), and herpes simplex virus promoter. In addition, sequences derived from non-viral genes, such as the murine metallothionein gene, also provide useful promoter sequences. Expression may be either constitutive or regulated (inducible), depending on the promoter can be induced with glucocorticoid in hormone-responsive cells.

15 The presence of an enhancer element (enhancer), combined with the promoter elements described above, will usually increase expression levels. An enhancer is a regulatory DNA sequence that can stimulate transcription up to 1000-fold when linked to homologous or heterologous promoters, with synthesis beginning at the normal RNA start site. Enhancers are also active when they are placed upstream or downstream from
20 the transcription initiation site, in either normal or flipped orientation, or at a distance of more than 1000 nucleotides from the promoter [Maniatis et al. (1987) *Science* 236:1237; Alberts et al. (1989) *Molecular Biology of the Cell*, 2nd ed.]. Enhancer elements derived from viruses may be particularly useful, because they usually have a broader host range. Examples include the SV40 early gene enhancer [Dijkema et al
25 (1985) *EMBO J.* 4:761] and the enhancer/promoters derived from the long terminal repeat (LTR) of the Rous Sarcoma Virus [Gorman et al. (1982b) *Proc. Natl. Acad. Sci.* 79:6777] and from human cytomegalovirus [Boshart et al. (1985) *Cell* 41:521]. Additionally, some enhancers are regulatable and become active only in the presence of an inducer, such as a hormone or metal ion [Sassone-Corsi and Borelli (1986) *Trends*
30 *Genet.* 2:215; Maniatis et al. (1987) *Science* 236:1237].

A DNA molecule may be expressed intracellularly in mammalian cells. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, the N-terminus may be cleaved from the protein by *in vitro* incubation with cyanogen bromide.

Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in mammalian cells. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either *in vivo* or *in vitro*. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The adenovirus tripartite leader is an example of a leader sequence that provides for secretion of a foreign protein in mammalian cells. Usually, transcription termination and polyadenylation sequences recognised by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. The 3' terminus of the mature mRNA is formed by site-specific post-transcriptional cleavage and polyadenylation [Birnstiel et al. (1985) *Cell* 41:349; Proudfoot and Whitelaw (1988) "Termination and 3' end processing of eukaryotic RNA. In *Transcription and splicing* (ed. B.D. Hames and D.M. Glover); Proudfoot (1989) *Trends Biochem. Sci.* 14:105]. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator/polyadenylation signals include those derived from SV40 [Sambrook et al (1989) "Expression of cloned genes in cultured mammalian cells." In *Molecular Cloning: A Laboratory Manual*].

Some genes may be expressed more efficiently when introns (also called intervening sequences) are present. Several cDNAs, however, have been efficiently expressed from vectors that lack splicing signals (also called splice donor and acceptor sites) [see e.g., Gothing and Sambrook (1981) *Nature* 293:620]. Introns are intervening noncoding sequences within a coding sequence that contain splice donor and acceptor sites. They are removed by a process called "splicing," following polyadenylation of the primary

transcript [Nevins (1983) *Annu. Rev. Biochem.* 52:441; Green (1986) *Annu. Rev. Genet.* 20:671; Padgett et al. (1986) *Annu. Rev. Biochem.* 55:1119; Krainer and Maniatis (1988) "RNA splicing." In *Transcription and splicing* (ed. B.D. Hames and D.M. Glover)].

5

Usually, the above described components, comprising a promoter, polyadenylation signal, and transcription termination sequence are put together into expression constructs. Enhancers, introns with functional splice donor and acceptor sites, and leader sequences may also be included in an expression construct, if desired. Expression
10 constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as mammalian cells or bacteria. Mammalian replication systems include those derived from animal viruses, which require trans-acting factors to replicate. For example, plasmids containing the replication systems of papovaviruses, such as SV40 [Gluzman (1981) *Cell* 23:175] or
15 polyomavirus, replicate to extremely high copy number in the presence of the appropriate viral T antigen. Additional examples of mammalian replicons include those derived from bovine papillomavirus and Epstein-Barr virus. Additionally, the replicon may have two replicaton systems, thus allowing it to be maintained, for example, in mammalian cells for expression and in a prokaryotic host for cloning and amplification.
20 Examples of such mammalian-bacteria shuttle vectors include pMT2 [Kaufman et al. (1989) *Mol. Cell. Biol.* 9:946 and pHEBO [Shimizu et al. (1986) *Mol. Cell. Biol.* 6:1074].

The transformation procedure used depends upon the host to be transformed. Methods
25 for introduction of heterologous polynucleotides into mammalian cells are known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

Mammalian cell lines available as hosts for expression are known in the art and include
30 many immortalised cell lines available from the American Type Culture Collection (ATCC), including but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells,

baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), and a number of other cell lines.

5 The polynucleotide encoding the protein can also be inserted into a suitable insect expression vector, and is operably linked to the control elements within that vector. Vector construction employs techniques that are known in the art. Generally, the components of the expression system include a transfer vector, usually a bacterial plasmid, which contains both a fragment of the baculovirus genome, and a convenient restriction site for insertion of the heterologous gene or genes to be expressed; a wild
10 type baculovirus with a sequence homologous to the baculovirus-specific fragment in the transfer vector (this allows for the homologous recombination of the heterologous gene in to the baculovirus genome); and appropriate insect host cells and growth media.

15 After inserting the DNA sequence encoding the protein into the transfer vector, the vector and the wild type viral genome are transfected into an insect host cell where the vector and viral genome are allowed to recombine. The packaged recombinant virus is expressed and recombinant plaques are identified and purified. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, *inter alia*, Invitrogen, San Diego CA ("MaxBac" kit). These techniques are
20 generally known to those skilled in the art and fully described in Summers and Smith, *Texas Agricultural Experiment Station Bulletin No. 1555 (1987)* (hereinafter "Summers and Smith").

25 Prior to inserting the DNA sequence encoding the protein into the baculovirus genome, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are usually assembled into an intermediate transplacement construct (transfer vector). This construct may contain a single gene and operably linked regulatory elements; multiple genes, each with its owned set of operably linked regulatory elements; or multiple genes, regulated by the
30 same set of regulatory elements. Intermediate transplacement constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as a bacterium. The replicon will have a

replication system, thus allowing it to be maintained in a suitable host for cloning and amplification.

Currently, the most commonly used transfer vector for introducing foreign genes into AcNPV is pAc373. Many other vectors, known to those of skill in the art, have also been designed. These include, for example, pVL985 (which alters the polyhedrin start codon from ATG to ATT, and which introduces a BamHI cloning site 32 basepairs downstream from the ATT; see Luckow and Summers, *Virology* (1989) 17:31.

- 10 The plasmid usually also contains the polyhedrin polyadenylation signal (Miller et al. (1988) *Ann. Rev. Microbiol.*, 42:177) and a prokaryotic ampicillin-resistance (*amp*) gene and origin of replication for selection and propagation in *E. coli*.

Baculovirus transfer vectors usually contain a baculovirus promoter. A baculovirus promoter is any DNA sequence capable of binding a baculovirus RNA polymerase and initiating the downstream (5' to 3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site. A baculovirus transfer vector may also have a second domain called an enhancer, which, if present, is usually distal to the structural gene. Expression may be either regulated or constitutive.

Structural genes, abundantly transcribed at late times in a viral infection cycle, provide particularly useful promoter sequences. Examples include sequences derived from the gene encoding the viral polyhedron protein, Friesen et al., (1986) "The Regulation of Baculovirus Gene Expression," in: *The Molecular Biology of Baculoviruses* (ed. Walter Doerfler); EPO Publ. Nos. 127 839 and 155 476; and the gene encoding the p10 protein, Vlasko et al., (1988), *J. Gen. Virol.* 69:765.

30

DNA encoding suitable signal sequences can be derived from genes for secreted insect or baculovirus proteins, such as the baculovirus polyhedrin gene (Carbonell et al. (1988)

Gene, 73:409). Alternatively, since the signals for mammalian cell posttranslational modifications (such as signal peptide cleavage, proteolytic cleavage, and phosphorylation) appear to be recognised by insect cells, and the signals required for secretion and nuclear accumulation also appear to be conserved between the
5 invertebrate cells and vertebrate cells, leaders of non-insect origin, such as those derived from genes encoding human γ -interferon, Maeda et al., (1985), *Nature* 315:592; human gastrin-releasing peptide, Lebacq-Verheyden et al., (1988), *Molec. Cell. Biol.* 8:3129; human IL-2, Smith et al., (1985) *Proc. Nat'l Acad. Sci. USA*, 82:8404; mouse IL-3, (Miyajima et al., (1987) *Gene* 58:273; and human glucocerebrosidase, Martin et al.
10 (1988) *DNA*, 7:99, can also be used to provide for secretion in insects.

A recombinant polypeptide or polyprotein may be expressed intracellularly or, if it is expressed with the proper regulatory sequences, it can be secreted. Good intracellular expression of non-fused foreign proteins usually requires heterologous genes that
15 ideally have a short leader sequence containing suitable translation initiation signals preceding an ATG start signal. If desired, methionine at the N-terminus may be cleaved from the mature protein by *in vitro* incubation with cyanogen bromide.

Alternatively, recombinant polyproteins or proteins which are not naturally secreted can
20 be secreted from the insect cell by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in insects. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the translocation of the protein into the endoplasmic reticulum.

25

After insertion of the DNA sequence and/or the gene encoding the expression product precursor of the protein, an insect cell host is co-transformed with the heterologous DNA of the transfer vector and the genomic DNA of wild type baculovirus - usually by co-transfection. The promoter and transcription termination sequence of the construct
30 will usually comprise a 2-5kb section of the baculovirus genome. Methods for introducing heterologous DNA into the desired site in the baculovirus virus are known in the art. (See Summers and Smith *supra*; Ju et al. (1987); Smith et al., *Mol. Cell. Biol.*

(1983) 3:2156; and Luckow and Summers (1989)). For example, the insertion can be into a gene such as the polyhedrin gene, by homologous double crossover recombination; insertion can also be into a restriction enzyme site engineered into the desired baculovirus gene. Miller et al., (1989), *Bioessays* 4:91. The DNA sequence, when cloned in place of the polyhedrin gene in the expression vector, is flanked both 5' and 3' by polyhedrin-specific sequences and is positioned downstream of the polyhedrin promoter.

The newly formed baculovirus expression vector is subsequently packaged into an infectious recombinant baculovirus. Homologous recombination occurs at low frequency (between about 1% and about 5%); thus, the majority of the virus produced after cotransfection is still wild-type virus. Therefore, a method is necessary to identify recombinant viruses. An advantage of the expression system is a visual screen allowing recombinant viruses to be distinguished. The polyhedrin protein, which is produced by the native virus, is produced at very high levels in the nuclei of infected cells at late times after viral infection. Accumulated polyhedrin protein forms occlusion bodies that also contain embedded particles. These occlusion bodies, up to 15 μ m in size, are highly refractile, giving them a bright shiny appearance that is readily visualised under the light microscope. Cells infected with recombinant viruses lack occlusion bodies. To distinguish recombinant virus from wild-type virus, the transfection supernatant is plaqued onto a monolayer of insect cells by techniques known to those skilled in the art. Namely, the plaques are screened under the light microscope for the presence (indicative of wild-type virus) or absence (indicative of recombinant virus) of occlusion bodies. "Current Protocols in Microbiology" Vol. 2 (Ausubel et al. eds) at 16.8 (Supp. 10, 1990); Summers and Smith, *supra*; Miller et al. (1989).

Recombinant baculovirus expression vectors have been developed for infection into several insect cells. For example, recombinant baculoviruses have been developed for, *inter alia*: *Aedes aegypti*, *Autographa californica*, *Bombyx mori*, *Drosophila melanogaster*, *Spodoptera frugiperda*, and *Trichoplusia ni* (PCT Pub. No. WO 89/046699; Carbonell et al., (1985) *J. Virol.* 56:153; Wright (1986) *Nature* 321:718; Smith et al., (1983) *Mol. Cell. Biol.* 3:2156; and see generally, Fraser, *et al.* (1989) *In Vitro Cell. Dev. Biol.* 25:225).

Cells and cell culture media are commercially available for both direct and fusion expression of heterologous polypeptides in a baculovirus/expression system; cell culture technology is generally known to those skilled in the art. *See, e.g., Summers and Smith*
5 *supra.*

The modified insect cells may then be grown in an appropriate nutrient medium, which allows for stable maintenance of the plasmid(s) present in the modified insect host. Where the expression product gene is under inducible control, the host may be grown to
10 high density, and expression induced. Alternatively, where expression is constitutive, the product will be continuously expressed into the medium and the nutrient medium must be continuously circulated, while removing the product of interest and augmenting depleted nutrients. The product may be purified by such techniques as chromatography, e.g., HPLC, affinity chromatography, ion exchange chromatography, etc.;
15 electrophoresis; density gradient centrifugation; solvent extraction, or the like. As appropriate, the product may be further purified, as required, so as to remove substantially any insect proteins which are also secreted in the medium or result from lysis of insect cells, so as to provide a product which is at least substantially free of host debris, e.g., proteins, lipids and polysaccharides.

20

In order to obtain protein expression, recombinant host cells derived from the transformants are incubated under conditions which allow expression of the recombinant protein encoding sequence. These conditions will vary, dependent upon the host cell selected. However, the conditions are readily ascertainable to those of ordinary
25 skill in the art, based upon what is known in the art.

Bacterial expression techniques are known in the art. A bacterial promoter is any DNA sequence capable of binding bacterial RNA polymerase and initiating the downstream (3") transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter
30 will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site. A bacterial promoter may also

have a second domain called an operator, that may overlap an adjacent RNA polymerase binding site at which RNA synthesis begins. The operator permits negative regulated (inducible) transcription, as a gene repressor protein may bind the operator and thereby inhibit transcription of a specific gene. Constitutive expression may occur
5 in the absence of negative regulatory elements, such as the operator. In addition, positive regulation may be achieved by a gene activator protein binding sequence, which, if present is usually proximal (5') to the RNA polymerase binding sequence. An example of a gene activator protein is the catabolite activator protein (CAP), which helps initiate transcription of the lac operon in *Escherichia coli* (*E. coli*) [Raibaud *et al.*
10 (1984) *Annu. Rev. Genet.* 18:173]. Regulated expression may therefore be either positive or negative, thereby either enhancing or reducing transcription.

Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing
15 enzymes, such as galactose, lactose (*lac*) [Chang *et al.* (1977) *Nature* 198:1056], and maltose. Additional examples include promoter sequences derived from biosynthetic enzymes such as tryptophan (*trp*) [Goeddel *et al.* (1980) *Nuc. Acids Res.* 8:4057; Yelverton *et al.* (1981) *Nucl. Acids Res.* 9:731; U.S. Patent No. 4,738,921; EPO Publ. Nos. 036 776 and 121 775]. The *g*-laotamase (*bla*) promoter system [Weissmann (1981)
20 "The cloning of interferon and other mistakes." In *Interferon 3* (ed. I. Gresser)], bacteriophage lambda PL [Shimatake *et al.* (1981) *Nature* 292:128] and T5 [U.S. Patent No. 4,689,406] promoter systems also provide useful promoter sequences.

In addition, synthetic promoters that do not occur in nature also function as bacterial
25 promoters. For example, transcription activation sequences of one bacterial or bacteriophage promoter may be joined with the operon sequences of another bacterial or bacteriophage promoter, creating a synthetic hybrid promoter [U.S. Patent No. 4,551,433]. For example, the *tac* promoter is a hybrid *trp-lac* promoter comprised of both *trp* promoter and *lac* operon sequences that is regulated by the *lac* repressor
30 [Amann *et al.* (1983) *Gene* 25:167; de Boer *et al.* (1983) *Proc. Natl. Acad. Sci.* 80:21]. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. A naturally occurring promoter of non-bacterial origin can also be

coupled with a compatible RNA polymerase to produce high levels of expression of some genes in prokaryotes. The bacteriophage T7 RNA polymerase/promoter system is an example of a coupled promoter system [Studier *et al.* (1986) *J. Mol. Biol.* 189:113; Tabor *et al.* (1985) *Proc Natl. Acad. Sci.* 82:1074]. In addition, a hybrid promoter can also be comprised of a bacteriophage promoter and an *E. coli* operator region (EPO Publ. No. 267 851).

In addition to a functioning promoter sequence, an efficient ribosome binding site is also useful for the expression of foreign genes in prokaryotes. In *E. coli*, the ribosome binding site is called the Shine-Dalgarno (SD) sequence and includes an initiation codon (ATG) and a sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon [Shine *et al.* (1975) *Nature* 254:34]. The SD sequence is thought to promote binding of mRNA to the ribosome by the pairing of bases between the SD sequence and the 3' end of *E. coli* 16S rRNA [Steitz *et al.* (1979) "Genetic signals and nucleotide sequences in messenger RNA." In *Biological Regulation and Development: Gene Expression* (ed. R.F. Goldberger)]. To express eukaryotic genes and prokaryotic genes with weak ribosome-binding site [Sambrook *et al.* (1989) "Expression of cloned genes in *Escherichia coli*." In *Molecular Cloning: A Laboratory Manual*].

20

A DNA molecule may be expressed intracellularly. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by *in vitro* incubation with cyanogen bromide or by either *in vivo* or *in vitro* incubation with a bacterial methionine N-terminal peptidase (EPO Publ. No. 219 237).

25

Fusion proteins provide an alternative to direct expression. Usually, a DNA sequence encoding the N-terminal portion of an endogenous bacterial protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the bacteriophage lambda cell gene can be linked at the 5' terminus of a foreign gene and

30

expressed in bacteria. The resulting fusion protein preferably retains a site for a processing enzyme (factor Xa) to cleave the bacteriophage protein from the foreign gene [Nagai *et al.* (1984) *Nature* 309:810]. Fusion proteins can also be made with sequences from the *lacZ* [Jia *et al.* (1987) *Gene* 60:197], *trpE* [Allen *et al.* (1987) *J. Biotechnol.* 5:93; Makoff *et al.* (1989) *J. Gen. Microbiol.* 135:11], and *Chey* [EPO Publ. No. 324 647] genes. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (e.g. ubiquitin specific processing-protease) to cleave the ubiquitin from the foreign protein. Through this method, native foreign protein can be isolated [Miller *et al.* (1989) *Bio/Technology* 7:698].

Alternatively, foreign proteins can also be secreted from the cell by creating chimeric DNA molecules that encode a fusion protein comprised of a signal peptide sequence fragment that provides for secretion of the foreign protein in bacteria [U.S. Patent No. 4,336,336]. The signal sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). Preferably there are processing sites, which can be cleaved either *in vivo* or *in vitro* encoded between the signal peptide fragment and the foreign gene.

DNA encoding suitable signal sequences can be derived from genes for secreted bacterial proteins, such as the *E. coli* outer membrane protein gene (*ompA*) [Masui *et al.* (1983), in: *Experimental Manipulation of Gene Expression*; Ghayeb *et al.* (1984) *EMBO J.* 3:2437] and the *E. coli* alkaline phosphatase signal sequence (*phoA*) [Oka *et al.* (1985) *Proc. Natl. Acad. Sci.* 82:7212]. As an additional example, the signal sequence of the alpha-amylase gene from various *Bacillus* strains can be used to secrete heterologous proteins from *B. subtilis* [Palva *et al.* (1982) *Proc. Natl. Acad. Sci. USA* 79:5582; EPO Publ. No. 244 042].

Usually, transcription termination sequences recognised by bacteria are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Transcription termination sequences frequently include DNA sequences of about 50 nucleotides capable of forming stem loop structures that aid in terminating transcription. Examples include transcription termination sequences derived from genes with strong promoters, such as the *trp* gene in *E. coli* as well as other biosynthetic genes.

10 Usually, the above described components, comprising a promoter, signal sequence (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as bacteria. The replicon will have a replication system, thus allowing it to be maintained in a prokaryotic host either for expression or for cloning and amplification. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably contain at least about 10, and more preferably at least about 20 plasmids. Either a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host.

Alternatively, the expression constructs can be integrated into the bacterial genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to the bacterial chromosome that allows the vector to integrate. Integrations appear to result from recombinations between homologous DNA in the vector and the bacterial chromosome. For example, integrating vectors constructed with DNA from various *Bacillus* strains integrate into the *Bacillus* chromosome (EPO Publ. No. 127 328). Integrating vectors may also be comprised of bacteriophage or transposon sequences.

Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of bacterial strains that have been transformed. Selectable markers can be expressed in the bacterial host and may include genes which render bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin (neomycin), and tetracycline [Davies *et al.* (1978) *Annu. Rev. Microbiol.* 32:469]. Selectable markers may also include biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways.

Alternatively, some of the above described components can be put together in transformation vectors. Transformation vectors are usually comprised of a selectable market that is either maintained in a replicon or developed into an integrating vector, as described above.

Expression and transformation vectors, either extra-chromosomal replicons or integrating vectors, have been developed for transformation into many bacteria. For example, expression vectors have been developed for, *inter alia*, the following bacteria: *Bacillus subtilis* [Palva *et al.* (1982) *Proc. Natl. Acad. Sci. USA* 79:5582; EPO Publ. Nos. 036 259 and 063 953; PCT Publ. No. WO 84/04541], *Escherichia coli* [Shimatake *et al.* (1981) *Nature* 292:128; Amann *et al.* (1985) *Gene* 40:183; Studier *et al.* (1986) *J. Mol. Biol.* 189:113; EPO Publ. Nos. 036 776, 136 829 and 136 907], *Streptococcus cremoris* [Powell *et al.* (1988) *Appl. Environ. Microbiol.* 54:655]; *Streptococcus lividans* [Powell *et al.* (1988) *Appl. Environ. Microbiol.* 54:655], *Streptomyces lividans* [U.S. Patent No. 4,745,056].

Methods of introducing exogenous DNA into bacterial hosts are well-known in the art, and usually include either the transformation of bacteria treated with CaCl₂ or other agents, such as divalent cations and DMSO. DNA can also be introduced into bacterial cells by electroporation. Transformation procedures usually vary with the bacterial species to be transformed. See e.g., [Masson *et al.* (1989) *FEMS Microbiol. Lett.* 60:273; Palva *et al.* (1982) *Proc. Natl. Acad. Sci. USA* 79:5582; EPO Publ. Nos. 036 259 and 063 953; PCT Publ. No. WO 84/04541, *Bacillus*], [Miller *et al.* (1988) *Proc. Natl. Acad. Sci.* 85:856; Wang *et al.* (1990) *J. Bacteriol.* 172:949, *Campylobacter*],

- [Cohen *et al.* (1973) *Proc. Natl. Acad. Sci.* 69:2110; Dower *et al.* (1988) *Nucleic Acids Res.* 16:6127; Kushner (1978) "An improved method for transformation of *Escherichia coli* with ColE1-derived plasmids. In *Genetic Engineering: Proceedings of the International Symposium on Genetic Engineering* (eds. H.W. Boyer and S. Nicosia);
- 5 Mandel *et al.* (1970) *J. Mol. Biol.* 53:159; Taketo (1988) *Biochim. Biophys. Acta* 949:318; *Escherichia*], [Chassy *et al.* (1987) *FEMS Microbiol. Lett.* 44:173 *Lactobacillus*]; [Fiedler *et al.* (1988) *Anal. Biochem* 170:38, *Pseudomonas*]; [Augustin *et al.* (1990) *FEMS Microbiol. Lett.* 66:203, *Staphylococcus*], [Barany *et al.* (1980) *J. Bacteriol.* 144:698; Harlander (1987) "Transformation of *Streptococcus lactis* by
- 10 electroporation, in: *Streptococcal Genetics* (ed. J. Ferretti and R. Curtiss III); Perry *et al.* (1981) *Infect. Immun.* 32:1295; Powell *et al.* (1988) *Appl. Environ. Microbiol.* 54:655; Somkuti *et al.* (1987) *Proc. 4th Evr. Cong. Biotechnology* 1:412, *Streptococcus*].
- 15 Yeast expression systems are also known to one of ordinary skill in the art. A yeast promoter is any DNA sequence capable of binding yeast RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region
- 20 usually includes an RNA polymerase binding site (the "TATA Box") and a transcription initiation site. A yeast promoter may also have a second domain called an upstream activator sequence (UAS), which, if present, is usually distal to the structural gene. The UAS permits regulated (inducible) expression. Constitutive expression occurs in the absence of a UAS. Regulated expression may be either positive or negative, thereby
- 25 either enhancing or reducing transcription.

Yeast is a fermenting organism with an active metabolic pathway, therefore sequences encoding enzymes in the metabolic pathway provide particularly useful promoter sequences. Examples include alcohol dehydrogenase (ADH) (EPO Publ. No. 284 044),

30 enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3-phosphate-dehydrogenase (GAP or GAPDH), hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and pyruvate kinase (PyK) (EPO Publ. No. 329 203). The

yeast *PHO5* gene, encoding acid phosphatase, also provides useful promoter sequences [Myanohara *et al.* (1983) *Proc. Natl. Acad. Sci. USA* 80:1].

In addition, synthetic promoters which do not occur in nature also function as yeast
5 promoters. For example, UAS sequences of one yeast promoter may be joined with the
transcription activation region of another yeast promoter, creating a synthetic hybrid
promoter. Examples of such hybrid promoters include the ADH regulatory sequence
linked to the GAP transcription activation region (U.S. Patent Nos. 4,876,197 and
4,880,734). Other examples of hybrid promoters include promoters which consist of the
10 regulatory sequences of either the *ADH2*, *GAL4*, *GAL10*, OR *PHO5* genes, combined
with the transcriptional activation region of a glycolytic enzyme gene such as GAP or
PyK (EPO Publ. No. 164 556). Furthermore, a yeast promoter can include naturally
occurring promoters of non-yeast origin that have the ability to bind yeast RNA
polymerase and initiate transcription. Examples of such promoters include, *inter alia*,
15 [Cohen *et al.* (1980) *Proc. Natl. Acad. Sci. USA* 77:1078; Henikoff *et al.* (1981) *Nature*
283:835; Hollenberg *et al.* (1981) *Curr. Topics Microbiol. Immunol.* 96:119;
Hollenberg *et al.* (1979) "The Expression of Bacterial Antibiotic Resistance Genes in
the Yeast *Saccharomyces cerevisiae*," in: *Plasmids of Medical, Environmental and*
Commercial Importance (eds. K.N. Timmis and A. Puhler); Mercerau-Puigalon *et al.*
20 (1980) *Gene* 11:163; Panthier *et al.* (1980) *Curr. Genet.* 2:109;].

A DNA molecule may be expressed intracellularly in yeast. A promoter sequence may
be directly linked with the DNA molecule, in which case the first amino acid at the N-
terminus of the recombinant protein will always be a methionine, which is encoded by
25 the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the
protein by *in vitro* incubation with cyanogen bromide.

Fusion proteins provide an alternative for yeast expression systems, as well as in
mammalian, baculovirus, and bacterial expression systems. Usually, a DNA sequence
30 encoding the N-terminal portion of an endogenous yeast protein, or other stable protein,
is fused to the 5' end of heterologous coding sequences. Upon expression, this construct
will provide a fusion of the two amino acid sequences. For example, the yeast or human

superoxide dismutase (SOD) gene, can be linked at the 5' terminus of a foreign gene and expressed in yeast. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. See e.g., EPO Publ. No. 196 056. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (e.g. ubiquitin-specific processing protease) to cleave the ubiquitin from the foreign protein. Through this method, therefore, native foreign protein can be isolated (*eg.* WO88/024066).

Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provide for secretion in yeast of the foreign protein. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either *in vivo* or *in vitro*. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell.

DNA encoding suitable signal sequences can be derived from genes for secreted yeast proteins, such as the yeast invertase gene (EPO Publ. No. 012 873; JPO Publ. No. 62,096,086) and the A-factor gene (U.S. Patent No. 4,588,684). Alternatively, leaders of non-yeast origin, such as an interferon leader, exist that also provide for secretion in yeast (EPO Publ. No. 060 057).

A preferred class of secretion leaders are those that employ a fragment of the yeast alpha-factor gene, which contains both a "pre" signal sequence, and a "pro" region. The types of alpha-factor fragments that can be employed include the full-length pre-pro alpha factor leader (about 83 amino acid residues) as well as truncated alpha-factor leaders (usually about 25 to about 50 amino acid residues) (U.S. Patent Nos. 4,546,083 and 4,870,008; EPO Publ. No. 324 274). Additional leaders employing an alpha-factor leader fragment that provides for secretion include hybrid alpha-factor leaders made with a presequence of a first yeast, but a pro-region from a second yeast alphafactor. (See e.g., PCT Publ. No. WO 89/02463.)

Usually, transcription termination sequences recognised by yeast are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator sequence and other yeast-recognised termination sequences, such as those coding for glycolytic enzymes.

Usually, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as yeast or bacteria. The replicon may have two replication systems, thus allowing it to be maintained, for example, in yeast for expression and in a prokaryotic host for cloning and amplification. Examples of such yeast-bacteria shuttle vectors include YEp24 [Botstein *et al.* (1979) *Gene* 8:17-24], pCl/1 [Brake *et al.* (1984) *Proc. Natl. Acad. Sci USA* 81:4642-4646], and YRp17 [Stinchcomb *et al.* (1982) *J. Mol. Biol.* 158:157]. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably have at least about 10, and more preferably at least about 20. Enter a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host. See e.g., Brake *et al.*, *supra*.

Alternatively, the expression constructs can be integrated into the yeast genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to a yeast chromosome that allows the vector to integrate, and preferably contain two homologous sequences flanking the expression construct. Integrations appear to result from recombinations between homologous DNA in the vector and the yeast chromosome [Orr-Weaver *et al.* (1983) *Methods in Enzymol.* 101:228-245]. An integrating vector may be directed to a specific locus in yeast by selecting the appropriate homologous sequence for inclusion in the vector. See Orr-Weaver *et al.*, *supra*. One or more expression construct may integrate, possibly affecting levels of recombinant protein produced [Rine *et al.* (1983) *Proc. Natl. Acad. Sci. USA* 80:6750].

The chromosomal sequences included in the vector can occur either as a single segment in the vector, which results in the integration of the entire vector, or two segments homologous to adjacent segments in the chromosome and flanking the expression construct in the vector, which can result in the stable integration of only the expression
5 construct.

Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of yeast strains that have been transformed. Selectable markers may include biosynthetic genes that can be expressed in the yeast
10 host, such as *ADE2*, *HIS4*, *LEU2*, *TRP1*, and *ALG7*, and the G418 resistance gene, which confer resistance in yeast cells to tunicamycin and G418, respectively. In addition, a suitable selectable marker may also provide yeast with the ability to grow in the presence of toxic compounds, such as metal. For example, the presence of *CUP1* allows yeast to grow in the presence of copper ions [Butt *et al.* (1987) *Microbiol. Rev.*
15 *51*:351].

Alternatively, some of the above described components can be put together into transformation vectors. Transformation vectors are usually comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector, as
20 described above.

Expression and transformation vectors, either extrachromosomal replicons or integrating vectors, have been developed for transformation into many yeasts. For example, expression vectors have been developed for, *inter alia*, the following
25 yeasts: *Candida albicans* [Kurtz, *et al.* (1986) *Mol. Cell. Biol.* 6:142], *Candida maltosa* [Kunze, *et al.* (1985) *J. Basic Microbiol.* 25:141], *Hansenula polymorpha* [Gleeson, *et al.* (1986) *J. Gen. Microbiol.* 132:3459; Roggenkamp *et al.* (1986) *Mol. Gen. Genet.* 202:302], *Kluyveromyces fragilis* [Das, *et al.* (1984) *J. Bacteriol.* 158:1165], *Kluyveromyces lactis* [De Louvencourt *et al.* (1983) *J. Bacteriol.* 154:737; Van den
30 Berg *et al.* (1990) *Bio/Technology* 8:135], *Pichia guilliermondii* [Kunze *et al.* (1985) *J. Basic Microbiol.* 25:141], *Pichia pastoris* [Cregg, *et al.* (1985) *Mol. Cell. Biol.* 5:3376; U.S. Patent Nos. 4,837,148 and 4,929,555], *Saccharomyces cerevisiae* [Hinnen *et al.*

(1978) *Proc. Natl. Acad. Sci. USA* 75:1929; Ito *et al.* (1983) *J. Bacteriol.* 153:163], *Schizosaccharomyces pombe* [Beach and Nurse (1981) *Nature* 300:706], and *Yarrowia lipolytica* [Davidow, *et al.* (1985) *Curr. Genet.* 10:380471 Gaillardin, *et al.* (1985) *Curr. Genet.* 10:49].

5

Methods of introducing exogenous DNA into yeast hosts are well-known in the art, and usually include either the transformation of spheroplasts or of intact yeast cells treated with alkali cations. Transformation procedures usually vary with the yeast species to be transformed. See e.g., [Kurtz *et al.* (1986) *Mol. Cell. Biol.* 6:142; Kunze *et al.* (1985) *J. Basic Microbiol.* 25:141; *Candida*]; [Gleeson *et al.* (1986) *J. Gen. Microbiol.* 132:3459; Roggenkamp *et al.* (1986) *Mol. Gen. Genet.* 202:302; *Hansenula*]; [Das *et al.* (1984) *J. Bacteriol.* 158:1165; De Louvencourt *et al.* (1983) *J. Bacteriol.* 154:1165; Van den Berg *et al.* (1990) *Bio/Technology* 8:135; *Kluyveromyces*]; [Cregg *et al.* (1985) *Mol. Cell. Biol.* 5:3376; Kunze *et al.* (1985) *J. Basic Microbiol.* 25:141; U.S. Patent Nos. 4,837,148 and 4,929,555; *Pichia*]; [Hinnen *et al.* (1978) *Proc. Natl. Acad. Sci. USA* 75:1929; Ito *et al.* (1983) *J. Bacteriol.* 153:163 *Saccharomyces*]; [Beach and Nurse (1981) *Nature* 300:706; *Schizosaccharomyces*]; [Davidow *et al.* (1985) *Curr. Genet.* 10:39; Gaillardin *et al.* (1985) *Curr. Genet.* 10:49; *Yarrowia*].

20 According to a further aspect of the present invention there is provided a method of production of a compound according to the first aspect of the present invention, comprising the steps of:

- a) immunising a mammal with an antibody against a capsular polysaccharide of group B *Streptococcus*;
- 25 b) removing spleen cells from the immunised mammal and selecting for cells that bind to the antibody;
- c) separating mRNA species from selected spleen cells and producing a phage library expressing proteins encoded by the mRNA species;
- d) selecting for recombinant phage expressing compounds of interest.

30

In order to immunise the mammal, an antibody against the capsular polysaccharide of group B *Streptococcus* (preferably type III CHO) is introduced, preferably parenterally, in an amount sufficient to elicit an immune response. The choice of mammal for

immunisation will depend largely upon the mammal for which the protective compound is intended. In most cases, this will be the human. Immunisation will most preferably utilise the antibody P9D8 (Teti *et al.*, 1992). Splenic lymphocytes are then removed from the immunised patient and cells are selected by antigen panning using the antibody
5 that was used for the initial immunisation as the coating antigen. mRNA from the selected lymphocytes is then used as a template for reverse transcriptase and the resulting cDNA can then be used to construct a recombinant phage library that expresses recombinant peptides, oligopeptides or polypeptides as fusion proteins with gIIIp. Phage expressing suitable candidate compounds on their surface may again be
10 selected by affinity purification using the antibody initially used for immunisation as the coating antigen. These phage can then be analysed using methods that will be readily apparent to those of skill in the art.

According to a further aspect of the present invention, there is provided a composition
15 comprising a peptide, oligopeptide, or polypeptide compound that is capable of eliciting a protective immune response against the capsular polysaccharide of group B *Streptococcus*, preferably the type III CHO of GBS, in conjunction with a pharmaceutically acceptable excipient. Such a composition may be used to provide protection against disease caused by pathogenic GBS bacteria and accordingly, may be
20 used as a vaccine. Vaccines according to the invention may either be prophylactic (*ie.* to prevent infection) or therapeutic (*ie.* to treat disease after infection).

By pharmaceutically-acceptable excipient is meant any compound that does not itself induce the production of antibodies harmful to the individual receiving the composition.
25 The excipient should be suitable for oral, subcutaneous, intramuscular, topical or intravenous administration. Suitable compounds are typically large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes) and inactive virus particles. Such compounds are well known to those of skill
30 in the art. Additionally, these compounds may function as immunostimulating agents (“adjuvants”). Furthermore, the antigen may be conjugated to a bacterial toxoid.

Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) aluminium salts (alum), such as aluminium hydroxide, aluminium phosphate, aluminium sulphate, *etc*; (2) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides or bacterial cell wall components), such as for example (a) MF59™ (WO 90/14837), containing 5% Squalene, 0.5% Tween™ 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE, although not required) formulated into submicron particles using a microfluidizer (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP either microfluidised into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) Ribi™ adjuvant system (RAS), containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (Detox™); (3) saponin adjuvants, such as Stimulon™ may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes); (4) Freund's complete and incomplete adjuvants (CFA & IFA); (5) cytokines, such as interleukins (*eg.* IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, *etc.*), interferons (*eg.* IFN γ), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), *etc*; and (6) other substances that act as immunostimulating agents to enhance the efficacy of the composition. Alum and MF59™ are preferred.

As mentioned above, muramyl peptides include, but are not limited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-*sn*-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), *etc.*

The immunogenic compositions (*eg.* the antigen, pharmaceutically acceptable carrier, and adjuvant) typically will contain diluents, such as water, saline, glycerol, ethanol, *etc.* Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles.

Typically, the immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid

vehicles prior to injection may also be prepared. The preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvanticity effect, as discussed above.

5 Immunogenic compositions used as vaccines comprise an immunologically effective amount of the antigenic polypeptides, as well as any other of the above-mentioned components, as needed. By "immunologically effective amount", it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of
10 individual to be treated (*eg.* non-human primate, primate, *etc.*), the capacity of the individual's immune system to synthesise antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.

15

The immunogenic compositions are conventionally administered parenterally *eg.* by injection, either subcutaneously or intramuscularly. They may also be administered to mucosal surfaces (*eg.* oral or intranasal), or in the form of pulmonary formulations, suppositories, or transdermal applications. Dosage treatment may be a single dose schedule
20 or a multiple dose schedule. The vaccine may be administered in conjunction with other immunoregulatory agents.

Peptide, oligopeptide, or polypeptide compounds according to the invention can also be used in immunoassays to detect antibody levels (or, conversely, antibodies directed
25 against the compounds of the present invention can be used to detect antigen levels). Immunoassays based on well-defined, recombinant antigens can be developed to replace invasive diagnostics methods. Antibodies to the compounds of the present invention within biological samples, including for example, blood or serum samples, can be detected. Design of the immunoassays is subject to a great deal of variation, and
30 a variety of these are known in the art. Protocols for the immunoassay may be based, for example, upon competition, or direct reaction, or sandwich type assays. Protocols may also, for example, use solid supports, or may be by immunoprecipitation. Most assays involve the use of labelled antibody or polypeptide; the labels may be, for example,

fluorescent, chemiluminescent, radioactive, or dye molecules. Assays which amplify the signals from the probe are also known; examples of which are assays which utilise biotin and avidin, and enzyme-labelled and mediated immunoassays, such as ELISA assays.

5

The invention also provides kits suitable for immunodiagnosis. These contain the appropriate labelled reagents and are constructed by packaging the appropriate materials, including the compositions of the invention, in suitable containers, along with the remaining reagents and materials (*eg.* suitable buffers, salt solutions, *etc.*) required for the conduct of the assay, as well as suitable set of assay instructions.

10

As an alternative to protein-based vaccines, DNA vaccination may be employed [*eg.* Robinson & Torres (1997) *Seminars in Immunology* 9:271-283; Donnelly *et al.* (1997) *Annu Rev Immunol* 15:617-648]. Accordingly, rather than comprise a peptide, oligopeptide, or polypeptide compound, the vaccines of the invention might comprise nucleic acid encoding these compounds.

15

According to a still further aspect of the present invention there is provided a method of prevention or treatment of a disease caused by GBS comprising introducing into a mammal, preferably a human, a compound or a composition that is capable of eliciting a protective immune response against the capsular polysaccharide of GBS in an effective amount.

20

According to a still further aspect of the present invention, there is provided a method of vaccinating a mammal, preferably a human, against a disease caused by GBS, comprising administering to the mammal a composition of a peptide, oligopeptide, or polypeptide compound according to the first aspect of the invention, optionally with a pharmaceutically-acceptable carrier such as an adjuvant.

25

According to a further embodiment of the present invention, there are also provided nucleic acid molecules encoding peptides, oligopeptides and polypeptides according to the first aspect of the invention. As will be apparent to the skilled artisan, the sequence of these nucleic acid molecules defines the amino acid sequence of the peptide,

30

oligopeptide or polypeptide that possesses the desired activity through the specificity of the genetic code.

5 Additionally, in order to precisely tailor the exact properties of the encoded compounds, the skilled artisan will appreciate that changes may be made at the nucleotide level from the peptide, oligopeptide or polypeptide sequence originally isolated, by addition, substitution, deletion or insertion of one or more nucleotides. Site-directed mutagenesis (SDM) is the method of preference used to generate mutated, improved compounds according to the present invention. There are many techniques of SDM now known to the skilled artisan, including oligonucleotide-directed mutagenesis using PCR as set out, for
10 example by Sambrook *et al.*, (1989) or using commercially available kits.

Most compounds produced by such techniques of mutagenesis will be less efficacious than those originally selected. However, in a minority of cases, the introduced mutations
15 will produce molecules with improved function, such as closer structural similarity to the type III CHO epitope of GBS, or greater immunogenicity in a certain organism.

The nucleic acid molecules according to this aspect of the present invention may comprise DNA, RNA or cDNA and may additionally comprise nucleotide analogues in
20 the coding sequence. Preferably, the nucleic acid molecules comprise DNA.

A further aspect of the present invention provides a host cell containing a nucleic acid encoding a compound according to the first aspect of the invention. A still further aspect provides a method comprising introducing the encoding nucleic acid into a host
25 cell or organism. Introduction of nucleic acid may employ any available technique, as discussed above.

In one embodiment, the nucleic acid is integrated into the genome of the host cell. Integration may be promoted by the inclusion of sequences that promote recombination
30 with the genome, in accordance with standard techniques (see Sambrook *et al.*, 1989).

Transgenic animals transformed so as to express or overexpress in the germ line one or more peptide, oligopeptide or polypeptide compounds according to the first aspect of the

present invention form a still further aspect of the invention, along with methods for their production.

5 Various aspects and embodiments of the present invention will now be described in more detail by way of example, with particular reference to scFv compounds isolated from a phage library. It will be appreciated that modification of detail may be made without departing from the scope of the invention. All publications, patents, and patent applications cited herein are incorporated in full by reference.

10 **BRIEF DESCRIPTION OF THE FIGURES**

Figure 1 shows anti-type III antibody levels in sera collected at various times after immunisation of mice with C10 scFv. Mice were immunised with purified C10 scFv or heat-killed GBS at the indicated times (arrows). Points and bars represent means \pm standard deviations of 5 determinations, each conducted on a different serum sample.

Figure 2 shows anti-type III antibody levels in sera collected at various times after immunisation with phage-displayed C10 scFv. Mice were immunised with phages expressing the C10 scFv or heat-killed GBS at the indicated times (arrows). Points and bars represent means \pm standard deviations of 5 determinations, each conducted on a different serum sample.

DETAILED DESCRIPTION OF THE INVENTION

25 Summary of standard procedures and techniques

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature *eg.* Sambrook *Molecular Cloning; A Laboratory Manual, Second Edition* (1989); *DNA Cloning, Volumes I and ii* (D.N Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait ed, 1984); *Nucleic Acid Hybridization* (B.D. Hames & S.J. Higgins eds. 1984); *Transcription and Translation* (B.D. Hames & S.J. Higgins eds. 1984);

Animal Cell Culture (R.I. Freshney ed. 1986); *Immobilised Cells and Enzymes* (IRL Press, 1986); B. Perbal, *A Practical Guide to Molecular Cloning* (1984); the *Methods in Enzymology* series (Academic Press, Inc.), especially volumes 154 & 155; *Gene Transfer Vectors for Mammalian Cells* (J.H. Miller and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory); Mayer and Walker, eds. (1987), *Immunochemical Methods in Cell and Molecular Biology* (Academic Press, London); Scopes, (1987) *Protein Purification: Principles and Practice*, Second Edition (Springer-Verlag, N.Y.), and *Handbook of Experimental Immunology, Volumes I-IV* (D.M. Weir and C. C. Blackwell eds 1986).

10

EXAMPLES

15 **Statistical analysis.**

Differences between antibody concentrations in mouse sera were analysed for statistical significance using one way analysis of variance and the Student-Keuls-Newman test. Differences in lethality were analysed with Fisher's exact test.

20

Bacterial strains and reagents.

Strain H738 (type III), was kindly provided by Dr. Bascom Anthony, National Institutes of Health, Bethesda, MD. Strain COH1 (also GBS type III) and the unencapsulated isogenic mutant COH1-13 were a gift of Dr. Craig Rubens, University of Washington, Seattle (Rubens *et al.*, 1987). Type III and group-specific CHOs were purified by ion-exchange chromatography and gel filtration from the culture supernatant of strain H738, as described previously (Mancuso *et al.*, 1994; von Hunolstein *et al.*, 1997). The type III CHO contained 24% sialic acid by weight (Aminoff, 1961). This preparation was considered of sufficient purity because it contained, on a weight basis, <0.5% proteins (BioRad protein assay, BioRad Laboratories, Milan, Italy) nucleic acids (absorbance at 250 nm) or rhamnose (Dische and Shettles, 1948), a major constituent of the group antigen.

The properties and purification of murine mAb P9D8 have been described elsewhere (Teti *et al.*, 1992). This mAb binds to a sialic acid-dependent epitope of the type III CHO, promotes opsonophagocytic killing of GBS and has significant protective activities against GBS-induced lethality when passively administered to neonatal rats or mice.

Rabbit anti-type III GBS serum (Statens Serum Institute, Copenhagen, Denmark) was absorbed with heat-killed (80° C for 45 min) unencapsulated GBS (strain COH1-13) to remove non-type specific anti-GBS antibodies. After absorption, this preparation reacted with type III GBS, but not with unencapsulated strains or strains belonging to other serotypes.

Production of phage libraries.

Phage libraries were produced using the following protocol. Male BALB/c mice (8 weeks old) were subcutaneously (s.c.) injected on days 0 and 15 with 50 µg of mAb P9D8 in 0.2 ml of complete Freund's adjuvant (Difco, distributed by Diagnostic International Distributors, Milan, Italy) and on days 21 and 28 with the same dose of antigen in 0.2 ml of incomplete Freund's adjuvant (Difco). A final booster injection (50 µg of antigen in saline) was given intraperitoneally on day 35, and three days later the mice were sacrificed and their spleens removed.

Spleen cells were resuspended in tissue culture medium and dispensed into 75 cm² tissue culture flasks previously coated with mAb P9D8 (25 µg/ml) in carbonate buffer (pH 9.6) and blocked with 2% non-fat dry milk (Sigma, Milan, Italy).

After overnight incubation at 37°C in 5% CO₂, non-adherent spleen cells were removed and mRNA was extracted from adherent cells directly in the panning flask using guanidium isothiocyanate. After purification by affinity chromatography on oligo(dT)-cellulose (QuickPrep mRNA purification kit, Pharmacia, Biotech, Milan, Italy), reverse-transcription of the purified mRNA was performed with a murine reverse transcriptase

by priming with random hexadeoxyribonucleotides, as described by Magliani *et al.*, (1997).

To clone and express antibody fragments, a commercial system (Recombinant Phage
5 Antibody System, Pharmacia) was used. The heavy and light chain antibody genes were amplified in two separate PCR reactions, by using two sets of specific primers, to generate 340 and 325 base pair fragments, respectively. The heavy and light chain DNA products were assembled into a single gene using a DNA fragment encoding a (Gly₄Ser)₃ linker, acting as a bridge between the carboxy-terminus of the V_H chain and
10 the amino-terminus of the V_L chain. The gene was then reamplified to introduce two restriction sites (*Sfi* I/*Not* I) for cloning into a specific phagemid vector (pCANTAB 5E).

The ligated vector, containing the scFv genes linked to a sequence encoding for a C-
15 terminal 13 amino acid peptide tag (E-tag) and followed by an amber translation stop codon, was introduced into a competent *supE E. coli* strain (TG1) which was then infected with the M13KO7 helper phage to yield recombinant phages displaying recombinant scFv antibodies on their tips.

20 **Phage selection.**

Phage selection was performed using the following protocol. Recombinant phages were dispensed to a 25cm² tissue culture flask that had been previously coated with 5 ml of mAb P9D8 (10 µg/ml) in carbonate buffer (pH 9.6). After an incubation of 2 hours at
25 37°C and extensive washing, log-phase TG1 cells were added to the flask and incubated at 37°C for 1 hour. The suspension was transferred into sterile tubes and, after the addition of ampicillin (100 µg/ml), glucose (2%) and M13KO7 helper phage, further incubated with shaking at 37°C. After production of the recombinant phage supernatant, a second round of panning was repeated and the cells plated onto ampicillin-containing
30 agar plates. Isolated colonies were transferred to separate wells of 96-well microtiter plates (master plates) which were then used for the library rescue with M13KO7.

Recombinant phage supernatants, obtained from the master plates were screened in the wells of microtiter plates previously coated with mAb P9D8 (10 µg/ml). 200µl of each supernatant, previously diluted with an equal volume of blocking buffer, were added to each antigen-coated well and incubated at room temperature for 2 hours. After 5 washings with 0.05% Tween 20 in PBS, bound phages were detected using 200 µl of peroxidase-conjugated sheep anti-M13 phage antibodies (Magliani *et al.*, 1997).

After two pannings of the library, six different phage clones produced strong reactions in ELISA tests using again wells coated with mAb P9D8. One of these clones, designated as C10, was selected for further characterisation. In addition, the irrelevant H6 scFv (Magliani *et al.*, 1997), which is unable to bind mAb P9D8, was selected as a control to be used throughout this study.

Production of scFv recombinant antibodies.

The recombinant phages giving a positive ELISA signal were used to infect *E. coli* HB2151 to produce soluble scFv recombinant antibodies.

Antigen-positive recombinant phages were used to infect log-phase HB2151 cells, which were exposed to 1mM EDTA to obtain periplasmic extracts. The scFv recombinant molecules were also obtained from concentrated supernatants of HB2151 cultures. Purification of scFv from either periplasmic extracts or supernatants was performed using an anti-E-tag N-hydroxysuccinimide activated Sepharose columns (HiTrap Anti-E-tag, Pharmacia) as described by Magliani *et al.*, (1997). During purification, scFv were detected by dot or western blot using anti-E-tag antibody.

After infection of *E. coli* HB2151 cells, C10 and the control H6 scFv were produced from either the periplasmic extracts or concentrated supernatants of the transformed strain. Since higher amounts were obtained from the supernatants (6 mg/l), these were used as a preferential source of scFv in subsequent studies. Western blot analysis of affinity purified C10 or H6 scFv showed that both consisted of single monomers with the approximate molecular weight of 29 kDa (not shown).

GBS agglutination inhibition assay.

In preliminary studies, soluble C10 and H6 scFv were tested for their ability to inhibit GBS agglutination by anti-type III antibodies.

5

A bacterial agglutination assay was set up by mixing killed GBS with type III-specific antibodies in U bottom-wells of microtiter plates. In this assay, type III GBS, but not unencapsulated mutants, were agglutinated by either mAb P9D8 or absorbed rabbit serum. For agglutination inhibition assay, inhibitors (50 μ l in PBS supplemented with 10 1% bovine serum albumin) were mixed with an equal volume of antibody-containing solutions in the wells of microtiter plates. Antibody solutions were adjusted to achieve final dilutions corresponding to two times the minimal concentration needed to induce agglutination in the absence of inhibitors. After incubating the inhibitors with type-specific antibody or absorbed rabbit serum for 30 minutes at 37°C, 50 μ l of the killed- 15 GBS suspension was added. This suspension was obtained after killing GBS strain H738 (type III) in 3% formalin (3 days at 4°C), and resuspending the washed pellet in PBS- albumin to a concentration of 5×10^8 cells/ml. The plates were incubated for 4 hours at 37°C and then overnight at room temperature. Results were assessed visually.

20 The specificity of the test for the type III CHO was confirmed by the ability of purified type-, but not group-specific antigen, to inhibit the agglutination of type III GBS by mAb P9D8 (Table 1). C10 scFv, at 15 μ g/ml or higher concentrations, was capable of inhibiting the agglutination of GBS cells induced by mAb P9D8. Significantly, up to 240 μ g/ml of the irrelevant H6 scFv did not affect agglutination (Table 1). The 25 inhibitory activities of C10 scFv suggested that the fragment recognised an idiotypic determinant of mAb P9D8 that was either close or identical to the paratopic combining site.

To discriminate between these two possibilities, agglutination-inhibition experiments 30 were performed using rabbit anti-type III antibodies, in place of mAb P9D8, to induce agglutination. The rationale behind these studies is that idiotypes unrelated to antigen binding are rarely present in antibodies raised in different species (Westerink *et al.*, 1990).

Table 1. Ability of anti-idiotypic scFv to inhibit GBS agglutination by type III-specific antibodies

Anti-type III antibody	Inhibitor	Agglutination
None	None	-
mAb P9D8 ascites ^a	None	+
mAb P9D8 ascites	Type III CHO (5µg/ml)	-
mAb P9D8 ascites	Group CHO (25µg/ml)	+
mAb P9D8 ascites	C10 scFv (240 µg/ml)	-
mAb P9D8 ascites	C10 scFv (120 µg/ml)	-
mAb P9D8 ascites	C10 scFv (60 µg/ml)	-
mAb P9D8 ascites	C10 scFv (30 µg/ml)	-
mAb P9D8 ascites	C10 scFv (15 µg/ml)	-
mAb P9D8 ascites	C10 scFv (7.5 µg/ml)	+
mAb P9D8 ascites	H6 scFv (240 µg/ml)	+
Absorbed rabbit serum ^b	None	+
Absorbed rabbit serum	Type III CHO (5µg/ml)	-
Absorbed rabbit serum	Group CHO (25µg/ml)	+
Absorbed rabbit serum	C10 scFv (240 µg/ml)	-
Absorbed rabbit serum	C10 scFv (120 µg/ml)	-
Absorbed rabbit serum	C10 scFv (60 µg/ml)	-
Absorbed rabbit serum	C10 scFv (30 µg/ml)	+
Absorbed rabbit serum	H6 scFv (240 µg/ml)	+

5 ^a Used at a final dilution of 1:125,000

^b Used at a final dilution of 1:500

Table 1 shows that the C10 scFv was capable of inhibiting agglutination induced by rabbit antibodies. This strongly suggested that C10 scFv was specific for the antigen-binding site of anti-type III CHO antibodies, and that could, therefore, mimic the conformation of the nominal type III antigen.

Immunisation with scFv.

In further experiments, mice were immunised with 50 µg of soluble C10 or H6 scFv in order to determine the nature of the immune response generated against these molecules.

Male BALB/c mice (6 weeks old) were immunised with either purified scFv or polyethylene glycol-NaCl precipitated phage-displayed scFv (Magliani *et al.*, 1997). A first subcutaneous injection of 50 µg of antigen in 0.2 ml of complete Freund's adjuvant was followed, after 2 weeks, by a second subcutaneous administration of the same dose in 0.2 ml of incomplete Freund's adjuvant. Three additional injections of 50 µg of immunogen in 0.2 ml of saline were given intraperitoneally at 21, 28 and 35 days after the initial immunisation.

20

Sera were obtained from the retroorbital plexus at the indicated times after immunisation and analysed for antibodies directed against the type III antigen using an enzyme-linked immunosorbent assay, in which microtiter plates were coated with 1 µg/well of tyrosylated type III CHO (Teti *et al.*, 1992). Bound antibodies were detected with biotinylated polyvalent anti-mouse IgG (Vector Laboratories, distributed by Labtek Milan, Italy) or with µ- or γ chain-specific alkaline phosphatase-horse anti-mouse Ig (Sigma, Milan, Italy), as described by Teti *et al.*, (1992a). A positive control consisting of pooled sera from mice immunised with killed type III GBS was included in each determination. Results were expressed in arbitrary units equal to the ratio between absorbance of test serum and absorbance of the positive control serum multiplied by 1,000.

30

Figure 1 shows ELISA results of serum samples (collected at the indicated times) tested for antibody levels by ELISA using the type III CHO as the coating antigen. Sera from mice vaccinated with C10 scFv showed significant ($p < 0.05$) elevations in anti-type III IgM and IgG, as compared with preimmune values (Figure 1). In contrast, sera from mice immunised with the control H6 scFv did not show any significant anti-type III CHO response (not shown). C10 scFv-induced anti-type III CHO antibody elevations were boosted by repeated vaccinations and slowly declined after the last immunisation with scFv at day 35 (Figure 1).

In order to determine if these immunisations primed the mice for responding to the nominal antigen, C10 scFv-immunised animals were boosted with killed type III GBS at day 97. Figure 1 shows that killed bacteria produced a sharp rise in anti-type III CHO antibodies as evidenced by higher titers of IgM, IgG and total antibodies at day 104, relative to day 97 values. These data indicated that C10 scFv could prime the mice for increased responses upon exposure to the pathogen.

Further studies were conducted to determine whether phages displaying the C10 scFv on their surface could also induce anti-type III CHO responses. Anti-type III CHO antibody responses in mice immunised with phage-displayed C10 fragments (Figure 2) were quite similar to those observed with purified C10 scFv using the same immunisation schedule and doses (i.e. 50 μ g of phages per mouse). Again, control phage-displayed H6 fragments were ineffective (not shown). These data suggest that presentation of the recombinant antiidiotypic fragments on the phage surface can be quite effective in inducing antibody responses, especially when taking into account that only 3-5 scFv molecules are expressed on the surface of each phage (Kortt *et al.*, 1994).

Neonatal model of GBS disease.

To study the protective effects of passively administered sera, a neonatal mouse model of GBS infection was used (Mancuso *et al.*, 1994; Cusumano *et al.*, 1996; Mancuso *et al.*, 1997) so that the ability of C10 scFv to passively protect pups against lethal infection with highly virulent GBS could be evaluated. The same model was also

employed to assess the efficacy of active maternal immunisation in protecting neonates from infection.

To assess the protective activity of sera, neonatal (24 h old) Balb/c mice were randomly assigned to control or experimental groups, marked and kept with the mother. Pups were inoculated subcutaneously with 25 μ l of the indicated dilutions of normal or immune sera. Six hours later, the animals were challenged subcutaneously with the COH1 strain (100 CFU in 25 μ l in PBS; a 90% lethal dose of GBS). Mortality was assessed every 12 hours for 5 days. Deaths rarely occurred after this time.

10

Table 2 shows that sera from either soluble or phage-displayed C10 scFv-immunised mice were capable of conferring significant passive immunoprotection against GBS challenge, as compared with preimmune sera. The protective titers of sera from C10 scFv-immunised mice ranged between 1:10 and 1:40 (Table 2). In contrast, sera from animals immunised with the irrelevant H6 scFv were non-protective (Table 2).

15

To determine whether maternal immunisation with antiidiotypic fragments was effective in protecting neonatal mice against infection, 4 weeks-old female mice were immunised 3 times with 50 μ g of soluble or phage-displayed scFv, mated and boosted again at 35 days after the initial immunisation. A first s.c. injection of 50 μ g of antigen in 0.2 ml of complete Freund's adjuvant was followed after 2 weeks by a second s.c. administration of the same dose in 0.2 ml of incomplete Freund's adjuvant. One additional injection of 50 μ g of immunogen in 0.2 ml of saline, was given s.c. at 21 days after the initial immunisation. Females were then mated at 31 days and boosted at 35 days with 50 μ g of antigen in saline administered s.c.

20

25

Neonatal pups were then infected with a 90% lethal dose of GBS. Table 3 shows that neonates born to mothers immunised with soluble or phage-displayed C10 scFv were significantly protected against GBS-induced lethality, relative to those born to mothers immunised with the irrelevant H6 scFv.

30

Table 2. Effects on lethality of sera from scFv-immunised mice in a neonatal model of GBS disease

Treatment	Serum dilutions				
	1:5	1:10	1:20	1:40	1:80
Preimmune serum	10/12 ^a	12/13	23/26	20/22	
Anti-H6 scFv serum	4/5	6/8	9/10		
Anti-C10 scFv serum no.1	0/4 ^b	0/5 ^b	1/10 ^b	2/10 ^b	4/7
Anti-C10 scFv serum no.2		0/9 ^b	1/13 ^b	7/8	
Anti-C10 scFv serum no.3		0/9 ^b	6/8	7/7	
Anti-C10 scFv serum no.4			1/10 ^b	3/10 ^b	4/4
Anti-C10 scFv serum no.5			2/12 ^b	7/10	
Anti-C10 phage-scFv no.1	0/10 ^b	2/8 ^b	10/10		
Anti-C10 phage-scFv no.2			0/5 ^b	0/4 ^b	4/5
Anti-C10 phage-scFv no.3			2/10 ^b	1/11 ^b	8/10

5 ^a Dead/total no. at 5 days after challenge. Shown are cumulative results from 5 experiments. Neonatal mice were injected s.c. with 20 µl of serum dilutions and infected with 100 CFU of GBS.

^b Significantly different from normal serum by Fisher's exact test

Table 3. GBS-induced lethality in neonatal mice born to mothers immunised with anti-idiotypic scFv.

Immunizing antigen	Neonatal lethality dead/total (%)
H6 scFv (control)	19/21(90)
C10 scFv	8/35 (23) ^a
phage-H6 scFv (control)	19/22(86)
phage-C10 scFv	5/31(16) ^a

5

^a Significantly different from control by Fisher's exact test

REFERENCES

Ahlers J.D., (1993) *J. Immunol.* **150**: 5647-5665.

- 5 Ala'Aldeen, D.A.A., & Hormaeche, C.E. (ed.). Molecular and clinical aspects of bacterial vaccine development. John Wiley & Sons, Chichester, U.K.(1995).

Aminoff, D. Methods for the quantitative estimation of N-acetylneuramic acid and their applications to hydrolisates of sialomucoids. *Biochem. J.* **81**,384-390 (1961).

10

Baker, C.J., Edwards, M.S., & Kasper, D.L. Role of antibody to native type III polysaccharide of group B streptococcus in infant infection. *Pediatrics* **68**,544-549 (1981).

- 15 Baker, C.J., Rench, M.A., Hickman, M.E., Paoletti, L.C. , & Kasper, D.L. Safety and immunogenicity of group B streptococcal (GBS) polysaccharide (PS) types Ia and Ib-tetanus toxoid (Ia-TT; Ib-TT) conjugate vaccines in women (abstract). *Pediatr. Res.* **39**,980A (1996).

- 20 Baker, C.J., & Edwards, M.S. Group B streptococcal infections. In: Remington J., Klein J.O., eds. *Infectious diseases of the fetus and newborn infant*. 4th ed. Philadelphia: W.B. Saunders, 980-1054 (1995).

- 25 Baker, C.J., & Kasper, D.L. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. *N. Engl.J.Med.* **294**,753-756 (1976).

Clackson and Wells (1994) *Trends Biotechnol* **12**: 173-184.

- 30 Cull *et al.* (1992) *P.N.A.S. USA* **89**: 1865-1869.

Cusumano, V. *et al.* Role of gamma interferon in a neonatal mouse model of group B streptococcal disease. *Infect. Immun.* **64**,2941-2944 (1996).

Dische, Z., & Shettles, R.B. A specific color reaction of methylpentoses and a spectrophotometric micromethod for their determination. *J. Biol. Chem.* **17**,595-599 (1948).

5

Friedberg *et al.*, (1995) *DNA repair and mutagenesis*. ASM Press, Washington.

Hoogenboom, (1997) *Trends Biotechnol.*, **15**, 62-70.

10 Kasper, D.L. *et al.* Immune response to type III streptococcal polysaccharide-tetanus toxoid conjugate vaccine. *J. Clin. Invest.* **98**,2308-2314 (1996).

Kortt, A.A. *et al.* Recombinant antineuraminidase single chain Fv antibody: characterisation, formation of dimer and higher molecular mass multimers and the
15 solution of the crystal structure of the scFv-neuraminidase complex. *Eur.J. Immunol.* **23**, 206-211 (1994).

Kowalczykowski *et al.*, (1994) *Microbiol Rev*, **58**: 401-465.

20 Kumar A, Arora R, Kaur P, Chauhan VS, Sharma P (1992) "Universal" T helper cell determinants enhance immunogenicity of a *Plasmodium falciparum* merozoite surface antigen peptide. *J Immunol* **148**: 1499-1505.

Larsonn, C., Stålhammar-Carlemalm, M., & Lindahl, G. Experimental vaccination
25 against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins rib and a. *Infect. Immun.* **64**,3518-3523 (1996).

Lett, E. *et al.*, (1994) *Infect Immun* 785-792.

30 Leung *et al.*, (1989) *Technique*, **1**: 11-15.

Liao *et al.*, (1986) *P.N.A.S. USA*, **83**: 576-580.

Madoff, L.C., Michel, J.L., Gong, E.W., Rodewald, A.K., & Kasper, D.L. Protection of neonatal mice from group B streptococcal infection by maternal immunisation with beta c protein. *Infect. Immun.* **60**,4989-4994 (1992).

5 Magliani, W. *et al.*. Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. *Nature Biotechnol.* **15**,155-158 (1997).

Mancuso, G. *et al.*. Beneficial effects of interleukin 6 in neonatal mouse models of group B streptococcal disease. *Infect. Immun.* **62**,4997-5002 (1994).

10

Mancuso, G. *et al.*. Role of interleukin 12 in experimental neonatal sepsis caused by group B streptococci. *Infect. Immun.* **65**,3731-3735 (1997).

15 Mancuso, G., Tomasello, F. , von Hünolstein, C., Orefici, G. , & Teti, G. Induction of tumour necrosis factor alpha by the group- and type-specific polysaccharides from type III group B streptococci. *Infect. Immun.* **62**:2748-2753 (1994).

Matteakis *et al.*, (1994) *P.N.A.S. USA* **91**: 9022-9026

20 McNamara, M., Ward, R.E., & Kohler, I.J. Monoclonal idiotype vaccine against *Streptococcus pneumoniae* infection. *Science* **226**,1325-1326 (1984).

Panina-Bordignon P, *et al.*, (1989) *Eur J Immunol.* **19**: 2237-2242.

25 Paoletti, L.C. *et al.*. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunisation with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. *Infect. Immun.* **62**,3236-3243 (1994).

30 Rubens, C.E., Wessels, M.R., Heggen, L.M., & Kasper, D.L. Transposon mutagenesis of group B streptococcal type III capsular polysaccharide: correlation of capsule expression with virulence. *Proc. Natl. Acad. Sci. USA* **84**,7208-7212 (1987).

Stein, K.E., & Soderstrom, T. Neonatal administration of idiotypic or anti-idiotypic primes for protection against *E. coli* K13 infection in mice. *J. Exp. Med.* **160**,1001-1041 (1984).

5 Stemmer, (1994) *Nature*, **370**: 389-391.

Teti, G. *et al.* Specificity and protective activity of murine monoclonal antibodies directed against the capsular polysaccharide of type III group B streptococci. *Hybridoma* **11**,13-22 (1992).

10

Teti, G., Tomasello, F., & Mancuso, G. Synthesis and immunological properties of an O-stearoyl polysaccharide from group B streptococci. *J. Immunol. Res.* **4**,67-72 (1992).

15

von Hunolstein, C. *et al.* Soluble antigens from group B streptococci induce cytokine production in human blood cultures. *Infect. Immun.* **65**,4017-4021 (1997).

Westerink, M.A., Campagnari, A.A., Wirth, M.A., & Apicella, M.A. Development and characterisation of an anti-idiotypic antibody to the capsular polysaccharide of *Neisseria meningitidis* serogroup C. *Infect. Immun.* **56**,1120-1127 (1988).

20

Westerink, M.A., Muller, E., & Apicella, M.A. Anti-idiotypic antibodies to bacterial capsular polysaccharides. in: *Idiotypic network and disease* (eds. Cerney, J. & Hiernaux, J.) p.107 to 119 (American Society for Microbiology, Washington, DC, 1990).

25

Winter *et al.*, (1994) *Annu Rev Immunol*, **12**, 433-55.

Yelamos *et al.*, (1995) *Nature*, **376**: 225-229.

30

Zaccolo *et al.*, (1996) *J Mol Biol* **255**: 589-603.

CLAIMS

1. A peptide, oligopeptide or polypeptide compound that is capable of eliciting a protective immune response against the capsular polysaccharide of group B
5 *Streptococcus*.
2. A compound according to claim 1 that is capable of eliciting a protective immune response against the type III capsular polysaccharide of group B *Streptococcus*.
- 10 3. The compound of claim 1 or 2 wherein the immune response comprises antibodies that bind to the compound.
4. The compound according to any preceding claim, wherein the immune response comprises T-cells that bind to the compound.
- 15 5. The compound according to any preceding claim, which comprises an antibody or antibody fragment.
6. The compound of claim 5 which comprises an scFv fragment.
- 20 7. The compound of claim 6 which is the scFv fragment C10.
8. The compound according to any preceding claim wherein the structure of the compound mimics an antigenic determinant of the capsular polysaccharide of group
25 B *Streptococcus*.
9. A compound according to claim 8 wherein the structure of the compound mimics an antigenic determinant of the type III capsular polysaccharide of group B
30 *Streptococcus*.
10. A compound according to any preceding claim, linked to a carrier protein that is effective to promote the delivery of the compound to the bloodstream of a patient or which promotes an immune response against the compound.

11. A pharmaceutical composition comprising a compound according to any preceding claim in conjunction with a pharmaceutically-acceptable excipient.
- 5 12. The composition according to claim 11 wherein the excipient is suitable for oral, subcutaneous, intramuscular, topical or intravenous administration.
13. A composition according to either of claims 11 or 12 additionally comprising an adjuvant.
- 10 14. A composition according to claim 13, wherein the adjuvant comprises alum.
15. The composition of claim 13, wherein the adjuvant comprises an oil-in-water emulsion
- 15 16. The compound according to any one of claims 1 to 10 or composition of any one of claims 11 to 15 for use as a protective immunogen in the control of diseases caused by GBS.
- 20 17. Use of the compound according to any one of claims 1 to 10 or composition of any one of claims 11 to 15 as a pharmaceutical.
18. Use of a compound according to any one of claims 1 to 10 or composition of any one of claims 11 to 15 in the manufacture of a medicament for the prevention or
- 25 treatment of a disease caused by GBS.
19. Use of a compound according to any one of claims 1 to 10 or composition of any one of claims 11 to 15 as a vaccine or vaccine component.
- 30 20. The compound according to any one of claims 1 to 10 or composition according to any one of claims 11 to 15 for use as a vaccine or as a component of a vaccine.

21. A vaccine comprising a compound according to any one of claims 1 to 10 or composition of any one of claims 11 to 15.
22. A method of selection of a compound according to any one of claims 1 to 10 comprising the steps of:
- 5
- a) immunising a mammal with an antibody against a capsular polysaccharide of group B *Streptococcus*;
 - b) removing spleen cells from the immunised mammal and selecting for cells that bind to the antibody;
 - 10 c) separating mRNA species from selected spleen cells and producing a phage library expressing proteins encoded by the mRNA species; and
 - d) selecting for recombinant phage expressing compounds of interest.
23. A method of prevention or treatment of a disease caused by GBS comprising 15 introducing into a mammal, preferably a human, a compound according to any one of claims 1 to 10 or a composition according to any of claims 11 to 15 in an effective amount.
24. A nucleic acid molecule which encodes a compound according to any one of claims 1 20 to 10.
25. The nucleic acid molecule of claim 24 which comprises DNA.
26. A cloning or expression vector comprising a nucleic acid molecule according to either 25 of claims 24 or 25.
27. A vector according to claim 26 which is a viral vector.
28. A host cell transformed or transfected with the nucleic acid of either of claims 24 or 25 30 or with the vector of either of claims 26 or 27.
29. A transgenic animal that has been transformed by a nucleic acid molecule according to either of claims 24 or 25 or by a vector according to either of claims 26 or 27.

30. A method of preparation of a compound according to any one of claims 1 to 10,
comprising expressing a vector according to claim 26 or 27 in a host cell and culturing
said host cell under conditions where said protein is expressed, and recovering said
5 protein thus expressed.




FIG. 1

2 / 2




FIG. 2

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 99/00799

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/11 C12N15/86 C07K14/315 C12N5/10 A61K39/09
 A61K39/39 A61K39/395 A61K47/48 C07K19/00 G01N33/577
 A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PINCUS SH ET AL.: "Peptides that mimic the group B streptococcal type III capsular polysaccharide antigen" JOURNAL OF IMMUNOLOGY, vol. 160, no. 1, 1 January 1998 (1998-01-01), pages 293-98, XP002102148 page 293, right-hand column page 295, left-hand column, paragraph 2 - page 296, left-hand column, paragraph 2 page 297, right-hand column, paragraph 2 - left-hand column tables I,II --- -/--	1-30

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search
15 July 1999

Date of mailing of the international search report
29/07/1999

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer
Covone, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 99/00799

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>LARSSON C ET AL.: "Experimental vaccination against group B Streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alfa" INFECTION AND IMMUNITY, vol. 63, no. 9, September 1996 (1996-09), pages 3518-23, XP002109333 cited in the application page 3518, left-hand column, paragraph 3 page 3518, right-hand column, paragraph 3 page 3519, right-hand column, paragraph 2 page 3521, right-hand column, paragraph 2 page 3522, right-hand column, paragraphs 2,3</p>	<p>1-4, 11-21,23</p>
X	<p>----- MADOFF LD ET AL.: "Protection of neonatal mice from group B streptococcal infection by maternal immunization with beta C protein" INFECTION AND IMMUNITY, vol. 60, no. 12, December 1992 (1992-12), pages 4989-94, XP002109334 cited in the application abstract table 3</p>	<p>1,3,4, 11-21,23</p>
P,X	<p>----- R FELDMAN ET AL: "The group B streptococcal capsular carbohydrate: Immune response and molecular mimicry" ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, vol. 435, no. 435, 1998, pages 261-269 269, XP002102149 ISSN: 0065-2598 page 262, paragraph 4 page 264, paragraph 1 page 269, paragraphs 2,3 -----</p>	<p>1-30</p>

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB 99/00799

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 17, 23
because they relate to subject matter not required to be searched by this Authority, namely:

see FURTHER INFORMATION sheet PCT/ISA/210
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/IB 99 00799

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 17, 23 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 17 23

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy